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Background—Transient receptor potential canonical type 6 (TRPC6) channels mediating 1-oleoyl-2-acetyl-sn-glycerol
(OAG)–induced calcium entry have been identified on human platelets. In the present study we tested the hypothesis
that hyperglycemia increases the expression of TRPC6 channels.
Methods and Results—Platelets from healthy control subjects and patients with type 2 diabetes mellitus were incubated with
glucose and calcium influx was measured using the fluorescent dye technique. TRPC channel protein expression was
investigated using immunofluorescence and fluorescence microscopy of single platelets. Administration of 25 mmol/L
glucose significantly enhanced the OAG-induced calcium influx, which was attenuated by inhibitors of the phosphatidyl-
inositol 3-kinase, wortmannin or LY294002. The glucose-enhanced and OAG-induced calcium influx was concentration- and
time-dependent. Glucose significantly increased the TRPC6 protein expression in platelets to 13112% (n33; P0.05),
whereas the expression of TRPC1, TRPC3, TRPC4, or TRPC5 were unchanged. The glucose-induced TRPC6 expression was
significantly attenuated in the presence of wortmannin or LY294002. Platelets from patients with type 2 diabetes mellitus
showed increased TRPC6 expression compared to nondiabetic individuals (P0.05).
Conclusion—The study indicates that high glucose increases TRPC6 channel protein expression on the platelet surface which
is mediated by a phosphatidylinositol 3-kinase–dependent pathway. (Arterioscler Thromb Vasc Biol. 2008;28:746-751)
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Cardiovascular complications including microangiopathy,retinopathy, neuropathy, nephropathy, and macroangi-
opathy are a frequent cause of morbidity and mortality in
patients with diabetes mellitus. It has been proposed that
platelets contribute to diabetic microangiopathy and mac-
roangiopathy.1,2 Platelets are an integral component of hemo-
stasis and contribute to the events leading to thrombosis and
atherosclerosis. Platelets in patients with type 2 diabetes
mellitus adhere to vascular endothelium and aggregate more
readily than those in healthy people. Complete activation of
platelets by stimulatory agents leads to an increase of cyto-
solic calcium levels, which triggers many intracellular signal-
ing processes important for the expression of functional
responses.3 Recently, transient receptor potential canonical
(TRPC) channels have been identified on human platelets.4,5
TRPC channels are nonselective cation channels mediating
cation influx including calcium influx into platelets. Recent
studies suggest that TRPC6 can be activated by the diacyl-
glycerol.6–8 For in vitro studies the membrane-permeant
diacylglycerol-analog 1-oleoyl-2-acetyl-sn-glycerol (OAG) is
often used to stimulate cation entry.6–8
In the present study we tested the hypothesis that hyper-
glycemia increases the expression of TRPC6 channels. We
observed a time- and concentration-dependent increase of
TRPC6 channel expression on the platelet surface after
administration of high glucose, which was accompanied by
an increased OAG-induced calcium influx. The glucose-
induced TRPC6 channel expression and the glucose-
enhanced OAG-induced calcium influx in platelets could be
blocked by inhibition of phosphatidylinositol 3-kinase. The
study indicates that high glucose is associated with increased
TRPC6 channel expression which is mediated by a phospha-
tidylinositol 3-kinase–dependent pathway.
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Methods
Platelet Preparation and
Fluorescence Measurements
Platelets were obtained from healthy control subjects or patients with
type 2 diabetes mellitus free from intercurrent illness. All donors
gave informed consent. The study was approved by the local ethics
committee. Subjects did not take antiplatelet drugs including aspirin
for at least 2 weeks. 20 mL blood was anticoagulated with 3.2%
trisodium citrate according to previously described methods.9,10
Blood was centrifuged at 240g for 10 minutes to obtain platelet rich
plasma, which was centrifuged at 240g for 15 minutes. Platelets were
resuspended in Hanks balanced salt solution containing (in mmol/L)
NaCl 136, KCl 5.40, CaCl2 1, KH2PO4 0.44, Na2HPO4 0.34,
N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid 10, pH 7.4
and incubated with 1 mol/L of the fluorescent dye 1-[2-(5-
Carboxyoxazol-2-yl)-6-aminobenzofuran-5-oxy]-2-(2-amino-5-
methylphenoxy)-ethane-N,N,NN-tetraacetic acid acetoxymethyes-
ter (fura2-AM; Merck Biosciences) for 60 minutes. After
centrifugation at 240g for 15 minutes to remove extraneous dye, the
platelet pellet was again resuspended in Hanks balanced salt solu-
tion. The platelet counts were adjusted to 1108 platelets/mL. To
exclude that the isolation procedure (including centrifugation and
washing procedures) affects platelet action we performed additional
experiments where platelets were isolated in the presence of
25 mmol/L glucose. Then platelets were exposed to 5.5 mmol/L
glucose or 25 mmol/L throughout all subsequent steps (including
loading with fura 2-AM).
Fluorescence measurements were undertaken as previously de-
scribed by our group using a 96-well fluorescent plate reader
(Fluoroskan Ascent Fluorometer, Thermo LabSystems Oy) at 510
nm emission with excitation wavelengths of 340 nm and 380 nm, and
the fluorescence ratio 340 nm/380 nm was calculated.11,12
Fluorescence measurements were performed after platelets had
been incubated for 60 minutes with buffer for control, or glucose
(25 mmol/L final concentration) in the absence or presence of
inhibitors of phosphatidylinositol 3-kinases, ie, wortmannin (final
concentration 20 mol/L) or 2-(4-Morpholinyl)-8-phenyl-4H-1-
benzopyran-4-one (LY294002, final concentration 10 mol/L). In-
creasing concentrations of the cell-permeable diacylglycerol analog,
1-oleoyl-2-acetyl-sn-glycerol (OAG), were used to activate the
platelets. The sustained calcium increase after administration of
OAG was determined. Some experiments were conducted in the
presence of an inhibitor of TRP channels, 1-[-[3-(4-methoxyphenyl)
propoxy]-4-methoxyphenethyl]-1H-imidazole (SKF-96365; Merck
Biosciences; final concentration, 10 mol/L)11,13,14 or in the presence of
the L-type calcium channel blocker, 2-[(2-Aminoethoxy)-methyl]-4-(2-
chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedi-carboxylic-acid-3-
ethyl-5-methyl-ester (amlodipine; Sigma-Aldrich; final concentration,
10 mol/L).
Platelet expression of P-selectin was measured as previously
described15 after platelets had been incubated for 60 minutes with
buffer for control or 25 mmol/L glucose. After fixation in parafor-
maldehyde, platelets were washed and incubated with mouse IgG
(nonspecific binding) and a monoclonal antibody against P-selectin
(both from Coulter Immunotech), followed by a secondary fluores-
cein isothiocyanate (FITC)-labeled antibody (Sigma-Aldrich). Flow
cytometry was thereafter performed (FACScan; Becton Dickinson).
Data are given as the median immunofluorescence intensity (arbi-
trary units) after subtraction of the nonspecific mouse IgG binding.
Immunofluorescence of TRP Channels
For the identification of TRPC channels, quantitative immunofluo-
rescence assays of human platelets were performed using the
Odyssey infrared imaging system (Licor Biosciences). Human plate-
lets in 96-well plates were incubated with rabbit anti-human TRPC1,
TRPC3, TRPC4, TRPC5, or TRPC6-antibodies (1:1000, Alomone
Labs, Jerusalem, Israel)11,12,16–18 for 2 hours, washed, incubated with
IRDye800CW-infrared fluorescent dye-conjugated goat antirabbit
antibodies (1:1000, Biomol) overnight at 4°C. Imaging was per-
formed at 810 nm emission with an excitation wavelength of 780 nm.
Monoclonal rat anti-human glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH; 1:1000; Serotec, Du¨sseldorf, Germany) antibodies
were used as internal reference after permeabilization. After incuba-
tion with Alexa Fluor680-allophycocyanin-fluorescence-labeled
goat anti-rat antibodies (1:1000, MoBiTec, Go¨ttingen, Germany)
imaging was performed at 700 nm emission with an excitation
wavelength of 680 nm. TRPC6 expression was analyzed under
control conditions and after administration of 25 mmol/L glucose. To
exclude osmotic effects platelets were also exposed to 25 mmol/L
urea or 25 mmol/L taurine.
Immunofluorescence staining of platelets from healthy subjects
was performed with specific TRPC6 antibodies and fluorescent
dye–labeled secondary antibodies and analyzed with a TE2000
Nikon microscopy. The fluorescence intensities obtained from mea-
surements of single platelets were averaged.
All substances were obtained from Sigma-Aldrich or Merck
Biosciences if not indicated otherwise.
Statistics
All data are presented as meanSEM of at least 3 to 10 independent
experiments, and were compared using a 2-tailed Student t test or
ANOVA as appropriate. A 2-sided probability value less than 0.05
was used to indicate statistical significance.
Results
In the present study we measured the effects of glucose on
TRPC channel expression and furthermore investigated
OAG-induced calcium influx (ie, channel activation by OAG)
in platelets.
Glucose Enhances the 1-oleoyl-2-acetyl-sn-glycerol
(OAG)-Induced Calcium Influx
Cytosolic calcium was measured in fura2-loaded platelets
that had been incubated in the absence and presence of
25 mmol/L glucose for 60 minutes (Figure 1A). Resting
cytosolic calcium in platelets was not significantly different
after incubation in the absence or presence of 25 mmol/L
glucose (F340 nm/F380 nm fluorescence ratio, 1.80.1 U
Figure 1. 1-oleoyl-2-acetyl-sn-glycerol (OAG)-induced calcium
influx in platelets treated with 25 mmol/L glucose (filled circles
or bars) or control buffer (open circles or bars) under control
conditions (A), in the presence of amlodipine (Amlo; B), or SKF-
96365 (SKF; C). Dose-response curve for glucose (D) and for
OAG (E). *P0.05.
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[n37] versus 1.70.1 U [n40]; P0.05). Platelets were
incubated under control conditions and with 25 mmol/L
glucose for 60 minutes. The administration of 60 mol/L
OAG increased the F340 nm/F380 nm fluorescence ratio in
glucose-treated platelets by 0.760.10 U and in control
platelets by 0.400.06 U (each n13). The OAG-induced
calcium influx was significantly higher in glucose-treated
platelets (P0.05). Next, we used the calcium channel
blocker amlodipine. In the presence of the L-type calcium
channel blocker amlodipine the OAG-induced calcium influx
was also higher in glucose-treated platelets compared to
control conditions (0.610.03 U versus 0.510.02 U; n10,
P0.05; Figure 1B). Furthermore, we used SKF-96365, an
inhibitor of TRP channels.11,13,14 In the presence of SKF-
96365 the OAG-induced calcium influx in glucose-treated
platelets was significantly reduced from 0.760.10 U (n13)
to 0.430.02 U (n10; P0.05). In the presence of SKF-
96365 the OAG-induced calcium influx was not significantly
different in glucose-treated platelets compared to control
conditions (0.430.02 U versus 0.380.04 U; each n10,
P0.05; Figure 1C). The glucose-enhanced OAG-induced
calcium influx was concentration-dependent (Figure 1D). As
shown in Figure 1E the effect of glucose on calcium influx
could be observed with different OAG concentrations.
To exclude that the isolation procedure affects platelet
action, the platelets were isolated in the presence of
25 mmol/L glucose. Then platelets were exposed to
5.5 mmol/L glucose or 25 mmol/L glucose throughout all
subsequent steps. These experiments confirmed that exposure
to 25 mmol/L glucose as compared to 5.5 mmol/L glucose
increased OAG-induced calcium influx into platelets
(0.860.05 U versus 0.480.03 U, each n15, P0.05).
Inhibition of Phosphatidylinositol 3-Kinase
Attenuates the Glucose-Enhanced OAG-Induced
Calcium Influx in Human Platelets
Because activation of phosphatidylinositol 3-kinase is
thought to be necessary for the translocation of TRPC
channels to the surface we examined the effects of specific
inhibitors of the phosphatidylinositol 3-kinase, wortmannin
or LY294002. In the presence of wortmannin or LY294002
the OAG-induced calcium increase after incubation with
25 mmol/L glucose was significantly attenuated (Figure 2A).
Compared to control conditions, wortmannin significantly
reduced the glucose-enhanced OAG-induced calcium in-
crease to 427% (P0.05; n6) and LY294002 signifi-
cantly reduced it to 361% (P0.05; n6; Figure 2B). As
indicated in Figure 2C the inhibitory effect of wortmannin on
glucose-enhanced OAG-induced calcium increase was dose-
dependent. These data indicate that high glucose concentra-
tions enhance OAG-induced calcium influx by a phosphati-
dylinositol 3-kinase-dependent mechanism.
Glucose Increases TRPC6 Channel Expression
in Platelets
It is well-known that OAG-induced calcium influx is at least
in part mediated through TRPC channels. Therefore we
evaluated whether glucose enhances the expression of TRPC
channels on human platelets. Using quantitative immunofluo-
rescence we observed an increased TRPC6 protein surface
expression after incubation of platelets with 25 mmol/L
glucose (Figure 3). The effects of glucose on TRPC6 expres-
sion were measured in 33 experiments. Glucose significantly
increased the TRPC6 expression to 13112% (n33;
P0.05). On the other hand glucose did not significantly
change the protein expression of TRPC1, TRPC3, TRPC4, or
TRPC5 (Figure 3B). The administration of 25 mmol/L urea
did not significantly affect TRPC6 protein surface expression
(1001%; n4; P0.05 compared to control conditions).
The administration of 25 mmol/L taurine did not significantly
affect TRPC6 expression (10210%; n5; P0.05 com-
pared to control), further excluding osmotic effects.
We also evaluated whether glucose increased the expres-
sion of P-selectin on human platelets using immunofluores-
cence and FACScan flow cytometry. Compared to control
conditions, the administration of 25 mmol/L glucose did not
significantly change the expression of P-selectin in platelets
(4.20.2 arbitrary units versus 4.30.4 arbitrary units; each
n8; P0.05).
To evaluate the effects of phosphatidylinositol 3-kinases
on TRPC6 expression we examined TRPC6 expression after
administration of glucose in the presence of inhibitors of the
phosphatidylinositol 3-kinase, wortmannin or LY294002. As
Figure 2. 1-oleoyl-2-acetyl-sn-glycerol (OAG)–induced calcium
influx in platelets treated with 25 mmol/L glucose (filled circles
or bars) plus wortmannin or plus LY294002 or control buffer
(open circles). Original tracings (A), summary data (B), and dose-
response curve for wortmannin. *P0.05.
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shown in Figure 4, glucose significantly increased the TRPC6
expression on the platelet surface to 1519% (n10;
P0.01). The increased TRPC6 expression after incubation
with 25 mmol/L glucose was significantly attenuated in the
presence of wortmannin to 996% (n4), or in the presence
of LY294002 it was significantly attenuated to 762% (n4;
each P0.01 compared to incubation with 25 mmol/L glu-
cose alone; Figure 4B). These results were also observed
using immunofluorescence of single platelets which were
analyzed by fluorescence microscopy (Figure 4C). Compared
to control conditions the administration of 25 mmol/L glu-
cose significantly increased the TRPC6 expression on the
platelet surface (1522%, n102; versus 1003%, n70;
P0.001).
As shown in Figure 5 the glucose-induced increase of
TRPC6 protein surface expression in platelets was time-
dependent. TRPC6 protein expression was significantly in-
creased after incubation with high glucose concentration for
at least 40 minutes.
Furthermore, we examined platelets from patients with
type 2 diabetes mellitus (mean age, 613 years; fasting blood
glucose 21232 mg/dL) and age-matched nondiabetic indi-
viduals (mean age, 624 years; fasting blood glucose 989
mg/dL). Platelets from patients with type 2 diabetes mellitus
showed increased TRPC6 expression compared to nondia-
betic individuals (27340% versus 10036%, each n5,
P0.05; Figure 5C).
Discussion
In the present study we investigated the effects of glucose on
TRPC channel expression, and furthermore we investigated
OAG-induced calcium influx (ie, channel activation by OAG)
in platelets. The study indicates that high glucose increases
TRPC6 channel protein expression which is mediated by a
phosphatidylinositol 3-kinase pathway. Furthermore, the in-
creased TRPC6 channel expression was associated with an
increased OAG-induced calcium influx. Altered platelet func-
tion in patients with diabetes mellitus and hyperglycemia
which causes accelerated atherosclerosis and increases the
risk of thrombotic events has been attributed to several
mechanisms including altered calcium homeostasis.19 Several
reports show increased agonist-induced calcium influx in
patients with diabetes mellitus.20,21 In accordance with these
reports the present study shows that high glucose signifi-
cantly enhances the OAG-induced calcium influx.
Which channels are responsible for increased OAG-
induced calcium influx in platelets exposed to high glucose?
It has been known for a long time that OAG induces calcium
influx and thereby activates platelets.22,23 TRPC channels are
likely candidates for mediating OAG-induced calcium influx.
First, Brownlow & Sage and Hassock et al reported the
presence of TRPC channels in human platelets.4,5 It is well
established that TRPC channels are nonselective cation chan-
Figure 3. Immunofluorescence assay of TRPC1, TRPC3,
TRPC4, TRPC5, and TRPC6 (green) normalized to GAPDH (red)
and overlay (yellow) on the surface of platelets treated with glu-
cose (filled bars) or control buffer (open bars). Representative
assay (A), summary data (B). *P0.05.
Figure 4. Immunofluorescence assay
of TRPC6 on the surface of platelets
treated with buffer as control or with
25 mmol/L glucose, glucose plus wort-
mannin (Wort) or plus LY294002 (LY).
Representative assay (A), summary data
(B). **P0.01 compared to control.
P0.01 compared to glucose.
TRPC6 expression on single platelets
treated with buffer (control) of glucose.
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nels that mediate calcium influx.24 TRPC6 channels have
been shown to be activated by the diacylglycerol analogue
OAG and thus to generate calcium entry.6–8 Second, using
different techniques (immunofluorescence and fluorescence
microscopy of single platelets) we showed that the incubation
of platelets with high glucose concentrations significantly
increased the TRPC6 protein expression on the platelet
surface in a dose- and time-dependent manner. When plate-
lets were incubated with high glucose the TRPC6 protein
expression on the platelet surface increased within 60 min-
utes. We verified that high glucose concentrations did not
significantly change the protein expression of TRPC1,
TRPC3, TRPC4, or TRPC5 channels in platelets, indicating a
selective mechanism. From these experiments we concluded
that prolonged exposure to high glucose enhances TRPC6
expression on the platelet surface and enhances agonist-
induced calcium influx.
Which mechanisms are involved mediating the increased
TRPC6 protein expression in platelets exposed to high
glucose? An increased protein expression on the cell surface
in the presence of high glucose has been described in several
cell types, including human cortical collecting duct and
human umbilical vein endothelial cells.25,26 Furthermore, high
glucose has been associated with increased number of glyco-
protein GPIIb/IIIa molecules on platelets.27 However, the
underlying mechanisms are only partly known. We may
speculate that glucose stimulation of platelets initiales the
rapid translocation of TRPC channels from vesicles held in
reserve just under the plasma membrane. A similar mecha-
nism had been postulated in human embryonic kidney cells
and neurons.28 It should be noted that P-selectin was not
significantly changed after administration of high glucose.
These findings are similar to those reported by Gresele et al
who showed that P-selectin expression on platelets did not
change significantly after hyperglycemic clamp.29 These
results indicated that the glucose-induced elevation of TRPC6
expression mainly predisposes to increased agonist-induced
calcium influx into platelets.
We found that the glucose-induced TRPC6 protein expres-
sion was significantly attenuated by inhibitors of the phos-
phatidylinositol 3-kinase, wortmannin or LY294002. Phos-
phatidylinositol 3-kinases are lipid kinases that phosphorylate
phosphoinositides on position 3 of their inositol head group.
The 2 main phosphoinositide products are phosphatidy-
linositol-3,4-phosphate and phosphatidylinositol-3,4,5-
phosphate. It has been recently shown that the activation of
phosphatidylinositol 3-kinase is necessary for the transloca-
tion of TRPC channels to the surface.28 Furthermore it has
been reported that high glucose directly activates the phos-
phatidylinositol 3-kinase activity.30 These data indicate that
high glucose increases phosphatidylinositol 3-kinase activity
which enhances the translocation of TRPC6 channels to the
platelet surface, and finally enhances platelet activation.
In summary the study shows that high glucose causes
increased TRPC6 channel protein expression on the platelet
surface which is mediated by a phosphatidylinositol 3-kinase
pathway.
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